Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Anticancer Research · 2026-08 · 46 (8) · 4443-4452
DOI: 10.21873/anticanres.18300 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Anticancer Research, online erschienen am 29.07.2026. Verfasst von Naoki Uchihara und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Liver Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
- Department of Gastroenterology and Hepatology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Japanese Red Cross Ise Hospital, Ise, Japan.
- Department of Gastroenterology and Hepatology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan.
- Department of Gastroenterology and Hepatology, Japanese Red Cross Maebashi Hospital, Maebashi, Japan.
- Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Ehime, Japan.
Zitieren
APA
Uchihara, N., Tamaki, N., Marusawa, H., Urawa, N., Hasebe, C., Arai, H., Ochi, H., Kondo, M., Mori, N., Tsuji, K., Fujii, H., Ogawa, C., Uchida, Y., Mori, H., Toshimori, J., Okamoto, E., Shigeno, M., Akahane, T., Narita, R., …, & Japanese Red Cross Liver Study Group (2026). Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Anticancer Research, 46(8), 4443-4452. https://doi.org/10.21873/anticanres.18300
Vancouver
Uchihara N, Tamaki N, Marusawa H, Urawa N, Hasebe C, Arai H, et al. Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Anticancer Research. 2026;46(8):4443-4452. doi:10.21873/anticanres.18300
BibTeX
@article{Uchihara2026,
author = {Uchihara, Naoki and Tamaki, Nobuharu and Marusawa, Hiroyuki and Urawa, Naohito and Hasebe, Chitomi and Arai, Hirotaka and Ochi, Hironori and Kondo, Masahiko and Mori, Nami and Tsuji, Keiji and Fujii, Hideki and Ogawa, Chikara and Uchida, Yasushi and Mori, Hiromitsu and Toshimori, Junichi and Okamoto, Eisuke and Shigeno, Masaya and Akahane, Takehiro and Narita, Ryoichi and Yoshida, Hideo and Yokohama, Keisuke and Kubotsu, Yoshihito and Yasuda, Yoichi and Tada, Toshifumi and Nakamura, Shinichiro and Tsuchiya, Kaoru and Yasui, Yutaka and Izumi, Namiki and Kurosaki, Masayuki and Japanese Red Cross Liver Study Group, Japanese Red Cross Liver Study Group},
title = {Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma},
journal = {Anticancer Research},
year = {2026},
volume = {46},
number = {8},
pages = {4443--4452},
doi = {10.21873/anticanres.18300}
}
EUVIMED